SCY-770 | SCYNEXIS, Inc.

SCY-770 is a novel, highly selective, clinical-stage direct AMPK activator under development as a new therapeutic approach for Autosomal Dominant Polycystic Kidney Disease (ADPKD). It directly activates AMPK, a key regulator of cellular metabolism, addressing the disease’s underlying metabolic abnormalities.